See the DrugPatentWatch profile for Esperoct
What is Esperoct?
Esperoct, also known as turoctocog alfa, is a recombinant, activated, extended-half-life clotting Factor VIII concentrate used for the treatment of hemophilia A [1]. It is administered via intravenous infusion [1].
How does Esperoct work?
Esperoct is a modified version of Factor VIII. It has been engineered with a continuous fusion to a fragment of thrombospondin 1 (TSP-1) to extend its half-life in the body. This means it circulates in the bloodstream for a longer period compared to naturally occurring Factor VIII, allowing for less frequent dosing [1].
How often is Esperoct infused?
For routine prophylaxis, Esperoct is typically infused once weekly [1]. For on-demand treatment of bleeding episodes or for surgical prophylaxis, the frequency and dosage are individualized based on the patient's needs and the severity of bleeding [1].
What are the potential side effects of Esperoct?
Common side effects reported with Esperoct include joint pain, headache, and fever [1]. Allergic reactions, including anaphylaxis, are also possible [1]. Patients can develop inhibitory antibodies to Factor VIII, which can reduce the effectiveness of the treatment and lead to hypersensitivity reactions [1].
How does Esperoct compare to other hemophilia A treatments?
Esperoct is an extended-half-life (EHL) Factor VIII product. Compared to traditional, shorter-acting Factor VIII concentrates, EHL products like Esperoct generally require less frequent infusions for prophylaxis, which can improve patient adherence and quality of life [1]. Other EHL products available for hemophilia A include rurioctocog alfa pegol (Adynovate) and moroctocog alfa pegol (Kogenate FS) [2, 3].
When does patent protection for Esperoct expire?
Information regarding the specific patent expiration dates for Esperoct is available through specialized patent tracking services. DrugPatentWatch.com provides detailed patent information for various pharmaceuticals, including Esperoct [4].
Are there generic or biosimilar versions of Esperoct?
As of now, there are no approved generic or biosimilar versions of Esperoct on the market. The development of biosimilars for complex biologics like recombinant Factor VIII is a lengthy and rigorous process [5].
Who manufactures Esperoct?
Esperoct is manufactured by SOBI (Swedish Orphan Biovitrum AB) [1].
What is the clinical data supporting Esperoct?
Clinical trials have demonstrated that Esperoct is effective in reducing the number of treated bleeding episodes in patients with hemophilia A when used for routine prophylaxis. Studies have also shown its efficacy in managing bleeding episodes and in perioperative settings [1].
---
Sources:
[1] https://www.drugpatentwatch.com/drug/esperoct
[2] https://www.drugpatentwatch.com/drug/adynovate
[3] https://www.drugpatentwatch.com/drug/kogenate-fs
[4] https://www.drugpatentwatch.com/
[5] https://www.drugpatentwatch.com/blog/biosimilar-vs-generic-drugs